Ekaterina Stolyarevich

Ekaterina Stolyarevich

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NCNatalia V. Chebotareva
Natalia V. Chebotareva
AVAnatoliy Vinogradov
Anatoliy Vinogradov
LTLarisa Tsoy
Larisa Tsoy
VVVladimir Varshavskiy
Vladimir Varshavskiy
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
Alexey S. KononikhinAlexey S. Kononikhin
Alexey S. Kononikhin
It is suggested that activated CD44+ cells play a profibrogenic role in the pathogenesis of active glomerulopathies. Complement activation is also involved in renal fibrogenesis. The aim of the study was to evaluate the role of the activation of CD44+ cells in the kidney tissue and complement components’ filtration to the urine as factors of renal tissue fibrosis in patients with glomerulopathies. In total, 60 patients with active glomerulopathies were included in our study: 29 patients with focal segmental glomerulosclerosis (FSGS), 10 patients with minimal change disease (MCD), 10 patients with membranous nephropathy (MN), and 11 patients with IgA nephropathy. The immunohistochemical peroxidase method was used to study the expression of CD44+ in kidney biopsies. Components of complement were analyzed in urine by the multiple reaction monitoring (MRM) approach using liquid chromatography. Strong CD44 expression was noted predominantly in PEC and mesangial cells (MC) in patients with FSGS, and to a lesser extent, in patients with MN and IgA nephropathy, and it was absent in patients with MCD. Expression of profibrogenic CD44+ in glomeruli correlated with the levels of proteinuria and complement C2, C3, and C9 components, and CFB and CFI in urine. The CD44+ expression scores in the renal interstitium correlated with the level of C3 and C9 components of complement in the urine and the area of tubulo-interstitial fibrosis. The strongest expression of CD44+ was found in the glomeruli (MC, PEC, and podocytes) of patients with FSGS compared with other glomerulopathies. The CD44 expression score in the glomeruli and interstitium is associated with high levels of complement components in the urine and renal fibrosis.

1 January 2020 in Nephrology and Dialysis
Verified
Journal Article
Closed access
M5Moscow City Hospital 52
Moscow City Hospital 52
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
ADA.I. Evdokimov Moscow State University of Medicine and Dentistry
A.I. Evdokimov Moscow State University of Medicine and Dentistry
SOShumakov National Medical Research Centre of Transplantology and Artificial Organs
Shumakov National Medical Research Centre of Transplantology and Artificial Organs
NFN.F. Frolova
N.F. Frolova
VVV.V. Varyasin
V.V. Varyasin

22 August 2021 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
Elena ZakharovaElena Zakharova
Elena Zakharova
AZAnastasiia Zykova
Anastasiia Zykova
TMTatyana Makarova
Tatyana Makarova
ELEugenia Leonova
Eugenia Leonova
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
ANCA-associated vasculitis (AAV) poses a significant risk of kidney failure; kidney biopsy remains a key prognostic tool. The histopathologic classification of AAV glomerulonephritis (GN) developed by Berden et al. showed correlation between GN classes and kidney outcomes; ANCA Renal Risk Score (ARRS) included tubular atrophy and interstitial fibrosis (TA/IF) as an additional parameter for risk assessment. We aimed to evaluate kidney survival across AAV GN classes and ARRS groups. A single-center retrospective study included 85 adult patients with biopsy-proven AAV kidney disease followed in the period of 2000–2020. Primary outcome was kidney survival at the end of 18 (5; 66) months follow-up, and kidney death was considered as stage 5 CKD. We found significant differences in kidney survival for sclerotic, mixed, crescentic and focal AAV GN classes: 19%, 76.2%, 91.7% and 100%, respectively (p = 0.009). Kidney survival was 0%, 75.6% and 100% for the high-, medium- and low-risk ARRS groups, respectively (p < 0.001); TA/IF analysis showed kidney survival at 49.6% vs. 87.7% for widespread and mild TA/IF, respectively (p = 0.003). Kidney survival was significantly lower in anti-MPO-ANCA versus anti-PR3-ANCA carriers (50.3% and 78.1%, respectively, p = 0.045). We conclude that unfavorable AAV kidney outcomes are associated with sclerotic GN class by Berden’s classification, ARRS high risk group, and anti-MPO-ANCA subtype.

1 January 2023 in Nephrology and Dialysis
Verified
Journal Article
Closed access
M5Moscow City Hospital 52
Moscow City Hospital 52
NBN.I. Belavina
N.I. Belavina
TRTrushkin
Trushkin
LAL.Yu. Artyukhina
L.Yu. Artyukhina
MDMoscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry
Moscow City Hospital 52; A.I. Evdokimov Moscow State University of Medicine and Dentistry
MUMoscow City Hospital 52; Pirogov Russian National Research Medical University (Pirogov Medical University)
Moscow City Hospital 52; Pirogov Russian National Research Medical University (Pirogov Medical University)

7 July 2024 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
MAMariam I. Akaeva
Mariam I. Akaeva
NKNatalia L. Kozlovskaya
Natalia L. Kozlovskaya
LBLarisa A. Bobrova
Larisa A. Bobrova
OVOLGA VOROBYEVA
OLGA VOROBYEVA
ESEkaterina Stolyarevich
Ekaterina Stolyarevich
АОАнаньева Анастасия Олеговна
Ананьева Анастасия Олеговна
Background. The spectrum of diseases characterized by the development of renal thrombotic microangiopathy (TMA) encompasses the malignant hypertension (MHT). TMA in MHT has conventionally been regarded as a variation of secondary TMA, the treatment of which is restricted to the stabilization of blood pressure levels, a measure that frequently fails to prevent the rapid progression to end-stage renal disease in patients. Nevertheless, there exists a rationale to suggest that, in certain instances, endothelial damage in MHT might be rooted in the dysregulation of the complement system (CS), thereby presenting potential opportunities for the implementation of complement-blocking therapy. Aim. To study clinical manifestations and genetic profile of CS in patients with morphologically confirmed renal TMA combined with severe AH. Materials and methods. 28 patients with morphologically verified renal TMA and severe AH were enrolled to the study. Patients with signs of microangiopathic hemolysis and thrombocytopenia were not included in the study due to possible compliance with the criteria for atypical hemolytic uremic syndrome (aHUS). The prevalence of rare genetic defects (GD) of the CS was assessed by molecular genetic analysis (search for mutations in the clinically significant part of the human genome – exome) by next-generation sequencing technology (NGS). Results. GD of CS were detected in a quarter of patients. Rare genetic variants classified as “likely pathogenic” including defects in CFI, C3, CD46, CFHR4, CFHR5 genes were detected in five cases. Two patients were found to have chromosomal deletions containing CFH-related proteins genes (CFHR1, CFHR3). Conclusion. Rare variants of CS genes linked to aHUS were found in 25% of patients with renal TMA, the genesis of which was originally thought to be secondary and attributed to MHT, with partial or complete absence of hematological manifestations of microangiopathic pathology. The key to confirming TMA associated with MHT, particularly in the absence of microangiopathic hemolysis and thrombocytopenia, elucidating its nature, and potentially effective complement-blocking therapy in patients with GD of CS, appears to be a genetic study of CS combined with a morphological study of a renal biopsy.

1 January 2024 in Nephrology and Dialysis
Verified
Journal Article
Closed access
Elena ZakharovaElena Zakharova
Elena Zakharova
RFRussian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
Russian Medical Academy of Continuing Professional Education of the Ministry of Health of the Russian Federation
ADA. I. Evdokimov Moscow State University of Medicine and Dentistry
A. I. Evdokimov Moscow State University of Medicine and Dentistry
AZAnastasiia Zykova
Anastasiia Zykova
TMT.A. Makarova
T.A. Makarova
ESE.V. Shutov
E.V. Shutov